Drug
Flt3 Ligand
Flt3 Ligand: highest development phase Phase 1/2, developed by Celldex Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Celldex Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FLT3 Ligand (CDX-301) NCT04491084 | Phase 1/2 | Non Small Cell Lung Cancer |
Latest
No recent events.
Follow Flt3 Ligand on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.